Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.

Morieri ML, Frison V, Rigato M, D'Ambrosio M, Tadiotto F, Paccagnella A, Simioni N, Lapolla A, Avogaro A, Fadini GP

The Journal of clinical endocrinology and metabolism1 Jul 2020Cited by 20 (Europe PMC)

PMID32301492DOI10.1210/clinem/dgaa204PepBankPUB-32301492

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In routine-care T2D patients, dulaglutide use was linked to a 1.0% HbA1c reduction at observation end.
In plain wordsIn routine-care patients with diabetes, dulaglutide use was linked to lower HbA1c than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseOverall HbA1c change
Study
n = 1,307
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · up to 30 monthsAs given in this study (human).
Measurements
HbA1c change
−1%
overall, end of observation
Source sentences
Summary
Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation.
2 context sentences(design, population, supporting numbers)
Summary · context
From a background population of 83,116 patients, 2084 initiated dulaglutide (15.3% switching from another GLP-1RA), 1307 of whom had at least 1 follow-up visit.
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
Report a problemFND-3230149201
02HumanObservational studyEfficacy outcome
In routine-care T2D patients, dulaglutide use was linked to a 2.9 kg weight reduction at observation end.
In plain wordsIn routine-care patients with diabetes, dulaglutide use was linked to lower weight than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseOverall body weight change
Study
n = 1,307
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · up to 30 monthsAs given in this study (human).
Measurements
Body weight change
−2.9 kg
overall, end of observation
Source sentences
Summary
Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation.
2 context sentences(design, population, supporting numbers)
Summary · context
From a background population of 83,116 patients, 2084 initiated dulaglutide (15.3% switching from another GLP-1RA), 1307 of whom had at least 1 follow-up visit.
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
Report a problemFND-3230149202
03HumanObservational studyEfficacy outcome
In routine-care T2D patients, HbA1c improvement with dulaglutide was significant across subgroups, including older, nonobese and chronic kidney disease patients.
In plain wordsIn patients with diabetes, dulaglutide use was linked to lower HbA1c across subgroups, including older patients and those with kidney disease.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c improvement across subgroups
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · up to 30 monthsAs given in this study (human).
Source sentences
Summary
Improvement in HbA1c was highly significant and consistent across all subgroups, including those aged ≥ 75 years, nonobese, or with chronic kidney disease.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
Report a problemFND-3230149207
04HumanObservational studyEfficacy outcome
In routine-care T2D patients, body weight declined in all dulaglutide subgroups.
In plain wordsIn patients with diabetes, dulaglutide use was linked to lower weight than baseline in all subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight decline across subgroups
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · up to 30 monthsAs given in this study (human).
Source sentences
Summary
Body weight declined in all subgroups and significantly more with the 1.5-mg versus 0.75-mg dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
Report a problemFND-3230149208
05HumanObservational studyEfficacy outcome
In routine-care T2D patients, weight declined significantly more with dulaglutide 1.5 mg than 0.75 mg.
In plain wordsIn patients with diabetes, dulaglutide 1.5 mg was linked to greater weight reduction than 0.75 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight decline by dose
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg · up to 30 monthsAs given in this study (human).
Source sentences
Summary
Body weight declined in all subgroups and significantly more with the 1.5-mg versus 0.75-mg dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
Report a problemFND-3230149209

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In routine-care T2D patients, HbA1c reductions with dulaglutide were more pronounced in GLP-1RA-naïve patients.
In plain wordsIn patients with diabetes, dulaglutide use was linked to greater HbA1c reductions without prior GLP-1RA use than with prior use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c effect by prior GLP-1RA use
Study
n: not reported in source
Comparator
Patients with prior GLP-1RA use
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
These effects were more pronounced in GLP-1RA-naïve patients and in those with shorter disease duration.
2 context sentences(design, population, supporting numbers)
Summary · context
Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation.
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3230149203
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In routine-care T2D patients, weight reductions with dulaglutide were more pronounced in GLP-1RA-naïve patients.
In plain wordsIn patients with diabetes, dulaglutide use was linked to greater weight reductions without prior GLP-1RA use than with prior use.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight effect by prior GLP-1RA use
Study
n: not reported in source
Comparator
Patients with prior GLP-1RA use
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
These effects were more pronounced in GLP-1RA-naïve patients and in those with shorter disease duration.
2 context sentences(design, population, supporting numbers)
Summary · context
Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation.
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3230149204
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In routine-care T2D patients, HbA1c reductions with dulaglutide were more pronounced with shorter disease duration.
In plain wordsIn patients with diabetes, dulaglutide use was linked to greater HbA1c reductions with shorter than longer disease duration.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c effect by disease duration
Study
n: not reported in source
Comparator
Longer disease duration
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
These effects were more pronounced in GLP-1RA-naïve patients and in those with shorter disease duration.
2 context sentences(design, population, supporting numbers)
Summary · context
Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation.
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3230149205
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In routine-care T2D patients, weight reductions with dulaglutide were more pronounced with shorter disease duration.
In plain wordsIn patients with diabetes, dulaglutide use was linked to greater weight reductions with shorter than longer disease duration.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight effect by disease duration
Study
n: not reported in source
Comparator
Longer disease duration
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
These effects were more pronounced in GLP-1RA-naïve patients and in those with shorter disease duration.
2 context sentences(design, population, supporting numbers)
Summary · context
Overall, dulaglutide reduced HbA1c by 1.0% and body weight by 2.9 kg at the end of observation.
Summary · context
Retrospective multicenter study.SettingDiabetes outpatient clinics.Patients and interventionAll consecutive patients who initiated dulaglutide between 2015 and 2018.Main outcome measuresChanges in HbA1c and body weight were assessed up to 30 months after baseline.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3230149206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.